Key facts
- This page summarizes Opaleye Management Inc.'s Form 4 filing for Tracon Pharmaceuticals, Inc..
- 2 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 14 Nov 2023, 16:05.
Opaleye Management Inc. - 10 Nov 2023 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 10 Nov 2023
- Net transaction value
- -$1,401,571
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2023, 16:05:15 UTC
- Prior SEC filing
- 20 Sep 2023
- Next SEC filing
- 22 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- Opaleye Management Inc., By: /s/ James Silverman, President
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Opaleye Management Inc. filed Form 4 for Tracon Pharmaceuticals, Inc. on 14 Nov 2023.
Change
- Previous filing in this sequence was filed on 20 Sep 2023.
- Current net transaction value: -$1,401,571.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCON
transaction
Common Stock, par value $0.001 per share
Sale
- Transaction value
- $1,272,123
- Shares
- -4,324,008
- Change %
- -100%
- Price
- $0.2942
- Shares after
- 0
- Date
- 10 Nov 2023
- Ownership
- By Opaleye, L.P.
- Footnotes
- F1, F3
TCON
transaction
Common Stock, par value $0.001 per share
Sale
- Transaction value
- $129,448
- Shares
- -440,000
- Change %
- -100%
- Price
- $0.2942
- Shares after
- 0
- Date
- 10 Nov 2023
- Ownership
- By Managed account
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TCON
holding
Derivative
Prefunded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,667,974
- Date
- 10 Nov 2023
- Ownership
- By Opaleye,L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,667,974
- Exercise price
- $0.0100
- Footnotes
- F1, F4
TCON
holding
Derivative
Prefunded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,358,993
- Date
- 10 Nov 2023
- Ownership
- By Opaleye,L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,358,993
- Exercise price
- $0.0100
- Footnotes
- F1, F4
TCON
holding
Derivative
Prefunded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,205,018
- Date
- 10 Nov 2023
- Ownership
- By Opaleye, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 2,205,018
- Exercise price
- $0.0100
- Footnotes
- F1, F4
TCON
holding
Derivative
Prefunded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,013,999
- Date
- 10 Nov 2023
- Ownership
- By Opaleye, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 2,013,999
- Exercise price
- $0.0100
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Opaleye Management Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund.
Footnote F2
Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to own the securities owned directly by the Managed Account beneficially.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
Footnote F4
The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.